Controversies in NEN : An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract
Open Access
- 9 August 2025
- journal article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (12) , e70080
Abstract
Grade 3 neuroendocrine tumours (NET G3) represent approximately 20% of high‐grade neuroendocrine neoplasms, and the recent identification of this entity has given rise to many unanswered questions relating to clinical management. The prognosis for these patients is worse than for those with Grade 1–2 well‐differentiated NET, but better than for those with Grade 3 poorly differentiated neuroendocrine carcinoma. This consensus statement aims to address some uncertainties and explore unmet needs in the management of patients with NET G3. Firstly, the role of surgery in localised disease will be discussed as well as the dilemma in relation to the use of neo‐adjuvant and/or adjuvant treatment in this setting. Treatment of oligometastatic digestive NET G3 will also be examined, including the positioning of surgery and ablative therapy. In the advanced setting, traditionally, chemotherapy in the form of temozolomide/capecitabine or 5‐fluorouracil‐based therapies, rather than platinum/etoposide, is considered a first‐line treatment option, with second‐line therapy dependent on what was used first‐line. More recently, following the results of the NETTER‐2 trial, Peptide Receptor Radionuclide Therapy with 177 Lu‐DOTATATE may be an option for selected patients with somatostatin receptor positive NET G3. There is limited data on the use of immunotherapy and targeted therapy in this disease group to date, and some available evidence will be presented. The role for re‐biopsy to guide treatment decision‐making in patients with digestive NET G3 and whether NET G3 outside of the digestive tract should be treated similarly will also be scrutinised. Prospective studies with translational end‐points are required to enable a better understanding of this diagnosis and to facilitate more optimal treatment discoveries.Keywords
This publication has 84 references indexed in Scilit:
- The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high‐grade transformationThe Journal of Pathology, 2024
- Role of Radioembolization in Metastatic Neuroendocrine TumorsCardioVascular and Interventional Radiology, 2022
- Surgical outcomes of gastro‐entero‐pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinomaJournal of Surgical Oncology, 2022
- Stellenwert der Chirurgie bei fernmetastasierten neuroendokrinen Neoplasien des PankreasDie Chirurgie, 2022
- Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine TumorsJAMA Network Open, 2022
- Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective ReviewThe Oncologist, 2021
- A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohortCancer, 2021
- "Present and future of immunotherapy in Neuroendocrine Tumors"Reviews in Endocrine and Metabolic Disorders, 2021
- Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine TumorsThe Oncologist, 2021
- Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasmsJournal of Cancer Research and Clinical Oncology, 2018